The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has
brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have …

Therapies directed at endocrine receptors and human epidermal growth factor receptor 2
are important treatment options for patients with breast cancer; however, drug resistance …

Many systemic treatment options are available for advanced breast cancer, including
endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) …

Background There is an unmet therapeutic need in endocrine-resistant, hormone receptor
(HR)-positive, human epidermal growth factor receptor 2-negative advanced breast cancer …

The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol
3‐kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth …

Background: Breast cancer cells can develop resistance to standard hormonal treatment
and chemotherapy with the activation of the mTOR pathway; this is supported by results of …

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With
Recurrent/Metastatic Breast Cancer: NCIC Clinic Page 1 Randomized Phase II Study …

Although patients with hormone receptor (HR)–positive breast cancer are successfully
treated with endocrine therapy, many tumors go on to develop resistance to these agents …

Purpose Cross-talk between signal transduction pathways likely contributes to hormone
resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian …

Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …